Effects of TGF-β/Smad3 Pathway on Process of Fulvestrant Inhibiting Proliferation and Secretion of Prolactinoma MMQ Cells

Chinese Journal of Pharmacovigilance ›› 2018, Vol. 15 ›› Issue (4): 193-196.

Effects of TGF-β/Smad3 Pathway on Process of Fulvestrant Inhibiting Proliferation and Secretion of Prolactinoma MMQ Cells

LIU Qian¹, LI Zhen-ye², CAO Lei², GAO Hua¹, LI Chu-zhong¹, ZHANG Ya-zhuo^1,*

1Beijing Neurosurgical Institute, Capital Medical University, Beijing 100050, China;
2Beijing Tiantan Hospital of Capital Medical University, Beijing 100050, China

Received:2018-05-29 Revised:2018-05-29 Online:2018-04-20 Published:2018-05-29

Abstract

Abstract: Objective To study the effects of TGF-β/Smad3 pathway on process of fulvestrant inhibiting the proliferation and secretion of prolactinoma MMQ cells. Methods After treated with different concentrations of fulvestrant for 24, 48, 72 h, the proliferation of prolactinoma MMQ cells was determined by MTS. Simultaneously, the active TGF-β; 1 and prolactin(PRL) levels in the supernatant of MMQ cells treated with increasing doses of fulvestrant for 24 h were measured by ELISA. The Smad3 phosphorylation levels following 24 h exposure to fulvestrant in MMQ cells were detected by immunofluorescence staining. Results Fulvestrant caused significant cytotoxicity in MMQ cells with a dose- and time-dependent manner. At the same time, MMQ cells were treated with fulvestrant increased active TGF-β; 1 levels and decreased PRL levels in a dose-dependent manner. In addition, the activated Smad3 in MMQ cells was significantly increased in cell cytoplasm and nucleus (mainly in cell nucleus) after following exposure to fulvestrant. Conclusion Fulvestrant maybe inhibit the proliferation and secretion of prolactin in MMQ cells through TGF- /Smad3 signaling pathway.

Key words: fulvestrant, estrogen receptor antagonist, TGF-β/Smad3 pathway;, prolactinoma, MMQ cell

CLC Number:

R965

LIU Qian, LI Zhen-ye, CAO Lei, GAO Hua, LI Chu-zhong, ZHANG Ya-zhuo. Effects of TGF-β/Smad3 Pathway on Process of Fulvestrant Inhibiting Proliferation and Secretion of Prolactinoma MMQ Cells[J]. Chinese Journal of Pharmacovigilance, 2018, 15(4): 193-196.

References

[1] Daly A F, Rixhon M, Adam C, et al.High prevalence of pituitary adenomas: a cross-sectional study in the province of Liege, Belgium[J]. J Clin Endocrinol Metab, 2006, 91(12):4769-4775.
[2] Gillam M P, Molitch M E, Lombardi G, et al.Advances in the treatment of prolactinomas[J]. Endocr Rev, 2006, 27(5):485-534.
[3] Colao A, Savastano S.Medical treatment of prolactinomas[J]. Nat. Rev. Endocrinol,2011, 7(5):267-278.
[4] Lloyd R V.Estrogen-induced hyperplasia and neoplasia in the rat anterior pituitary gland[J]. Am J Pathol, 1983, 113(2):198-206.
[5] Wakeling A E, Dukes M, Bowler J.A potent specific pure antiestrogen with clinical potential[J]. Cancer Res, 1991, 51(15):3867-3873.
[6] Gao H, Xue Y, Cao L, et al. ESR1 and its antagonist fulvestrant in pituitary adenomas[J]. Mol Cell Endocrinol, 2017,3(5):443:32-41.
[7] Recouvreux M V, Guida M C, Rifkin D B, et al.Active and total transforming growth factor-beta1 are differentially regulated by dopamine and estradiol in the pituitary[J]. Endocrinology,2011, 146(10):2722-2730.
[8] Ben-Jonathan N.Dopamine and transforming growth factor-beta1: an odd couple in growth inhibition of the lactotrophs[J]. Endocrinology, 2005, 146(10):4177-4178.
[9] Raverot G, Jouanneau E, Trouillas J.Management of endocrine disease: clinicopathological classification and molecular markers of pituitary tumours for personalized therapeutic strategies[J]. Eur J Endocrinol,2014,170(4):R121-132.
[10] 王涛,李士其,黄中.经蝶手术对男性青壮年垂体泌乳素腺瘤患者性腺功能的影响(附70例分析)[J].中国临床神经科学,2010,18(2):173-178.
[11] Grubisha M J, Cifuentes M E, Hammes S R.A local paracrine and endocrine network involving TGFbeta, Cox-2, ROS, and estrogen receptor beta influences reactive stromal cell regulation of prostate cancer cell motility[J]. Mol Endocrinol,2012, 26(6):940-954.
[12] Giacomini D, Paez-Pereda M, Stalla J, et al.Molecular interaction of BMP-4, TGF-beta, and estrogens in lactotrophs: impact on the PRL promoter[J]. Mol Endocrinol,2009,23(7):1102-1114.
[13] Heldin C H, Miyazono K, ten Dijke P. TGF-beta signalling from cell membrane to nucleus through SMAD proteins[J]. Nature,1997, 390(6659):465-471.
[14] Wolfraim L A, Fernandez T M, Mamura M, et al.Loss of Smad3 in acute T-cell lymphoblastic leukemia[J]. N Engl J Med, 2004, 351(6):552-559.